公司资料
Oric Pharmaceuticals, Inc. 股价、新闻与催化剂
- 股票代码:
- ORIC
- 交易所:
- NASDAQ
- 行业:
- Biopharma
- 所在地:
- United States
股票表现
13.38 USD (-3.53%)
收盘价
最后更新: 2026年8月17日
789M USD
市值
股价为何变动
As of Aug 17, 2026, ORIC closed down 3.53% at $13.38. No new same-company headline was identified in the current news window.
公司概览
Oncology Resistance Biology
ORIC Pharmaceuticals develops therapies intended to overcome mechanisms of treatment resistance in cancer. Its programs target epigenetic and signaling pathways that allow tumors to adapt to standard treatments.
Rinzimetostat
Rinzimetostat is an allosteric EED inhibitor that suppresses PRC2 activity. It is being developed with the androgen-receptor inhibitor darolutamide for metastatic castration-resistant prostate cancer after prior abiraterone treatment.
Himalayas-1
Himalayas-1 is the planned global Phase 3 registrational trial of rinzimetostat plus darolutamide in post-abiraterone metastatic castration-resistant prostate cancer. Dose-optimization results supported selection of 400 mg once daily as the recommended Phase 3 dose.
Enozertinib
Enozertinib is another clinical-stage ORIC oncology program approaching multiple data updates. The company intends to use these results to determine whether the asset is ready to enter registrational development.
未来催化剂
- Initiation of the Phase 3 Himalayas-1 trial expected in the first half of 2026.
- Multiple enozertinib clinical updates expected in the second half of 2026 ahead of a potential registrational trial.
近期新闻
- 01
- 02
- 03
- 04
- 05
相似股票
商业成熟度、治疗领域或催化剂模式相近的同行公司。